AbbVie: Dominating Immunology While Building Oncology Upside [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
In my view, this is directly related to the near-perfect complementarity of Rinvoq and Skyrizi, spanning indications, routes of administration, and mechanisms of action. The total net revenues of this 'duo' were about $25.87 billion in 2025, up 46.2% from 2024. Moreover, AbbVie has not abandoned its ambitions to gain a foothold in the oncology drugs market, including through partnerships with RemeGen, Genmab, and Neomorph. By opening this article, you'll learn more about why I believe AbbVie's bull run will continue into 2026. Zorica Nastasic/E+ via Getty Images AbbVie ( ABBV ), a leader in the JAK and IL-23 inhibitor markets, released strong Q4 numbers, but its stock price fell 5.1% that day. And first, I will note the dry numbers. So, its revenue rose 10.1% year-over-year to $16.6 billion This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such pos
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Notice to Convene the Annual General Meeting of Genmab A/S [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ:GMAB) had its price target raised by analysts at HC Wainwright from $39.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Genmab Publishes 2025 Annual ReportGlobeNewswire
- Genmab A/S (NASDAQ:GMAB) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $41.50 price target on the stock.MarketBeat